Umoja Biopharma
Wednesday, June 05, 2024
Cell and Gene Therapy and Genome Editing
Company Presentation Theater 1
Umoja is a transformative immunotherapy company creating off-the-shelf treatments that aim to extend the reach and effectiveness of CAR T cell therapies in oncology and autoimmunity. Our flagship technology is VivoVec, an in vivo delivery system that generates CAR T cells directly in a patient's body without the current complications and expense of today's first generation ex vivo CAR T cell therapies.
Company Website:
http://umoja-biopharma.com
Lead Product in Development:
UB-VV111, a gene therapy generating CD19 CAR T cells in vivo
Company HQ City
Seattle
Company HQ State
Washington
Company HQ Country
United States
CEO/Top Company Official
Andrew Scharenberg
Development Phase of Primary Product
Pre-Clinical
Primary Speaker
)
)
)
)
)
)
){kind=logo}
){kind=logo}
.png/fit-in/500x500/filters:no_upscale())